Sulfatinib
| CAS No. | 1816307-67-1 | Cat. No. | BCP19610 |
| Name | Sulfatinib | ||
| Synonyms | HMPL012;HMPL-012; HMPL 012; surufatinib; | ||
| Formula | C24H28N6O3S | M. Wt | 480.59 |
| Description | Sulfatinib, also known as surufatinib, is an orally bioavailable, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and the fibroblast growth factor receptor type 1 (FGFR1), with potential antineoplastic and anti-angiogenic activities. Upon oral administration, sulfatinib binds to and inhibits VEGFRs and FGFR1 thereby inhibiting VEGFR- and FGFR1-mediated signal transduction pathways. This leads to a reduction of angiogenesis and tumor cell proliferation in VEGFR/FGFR1-overexpressing tumor cells. Expression of VEGFRs and FGFR1 may be upregulated in a variety of tumor cell types. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | VEGFR FGFR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.